Novartis AG (NVS) : Mondays money flow analysis of Novartis AG (NVS) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $3.56 million. In comparison, the inflow of money on upticks was a meager $1.95 million. The dollar value of composite uptick trades minus the downtick trades was negative $1.62 million. The uptick to downtick ratio of 0.55 in the money flow shows weakness. The downtick transaction value was high at $1.35 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($1.35 million). Novartis AG (NVS) gained $0.19 at $82.27, a change of 0.23% over the previous days close.
Shares of Novartis AG rose by 0.07% in the last five trading days and 0.89% for the last 4 weeks. Novartis AG is up 8.87% in the last 3-month period. Year-to-Date the stock performance stands at -0.57%.
Novartis AG (NYSE:NVS): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $82.06 and $82.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $82.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $82.34, notching a gain of 0.32% for the day. The total traded volume was 990,970 . The stock had closed at $82.08 on the previous day.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.